Diversification, Not Genzyme, Is The Theme Of Sanofi's Year-End Financial Report
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi's sales declined by 1% in 2010 and net income increased by 2.6%, although €2 billion in sales were lost to generics during the year.
You may also be interested in...
Bayer Benefits From Diversification, Despite Flat Pharma Growth in 2010
Firm's ability to pursue smaller acquisitions or partnerships is improving because of a reduction in net debt.
Bayer Benefits From Diversification, Despite Flat Pharma Growth in 2010
Firm's ability to pursue smaller acquisitions or partnerships is improving because of a reduction in net debt.
Sanofi-Aventis Emerging Markets Sales Exceed U.S., Europe: Emerging Markets Earnings Round Up (Part 2)
Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.